David Lebwohl Leaves Novartis for Chief Medical Post at Semma

Semma Therapeutics has appointed David Lebwohl to serve as chief medical officer. Lebwohl comes to the Cambridge, MA, regenerative medicine company from Novartis (NYSE: [[ticker:NVS]]), where he was senior vice president and franchise global program head of the CAR-T team.

In other moves, Semma named David DiGiusto its chief technology officer. DiGiusto comes to Semma from Stanford University. Last year, Semma raised $114 million in Series B financing to support development of a diabetes treatment that uses embryonic stem cells to make insulin-producing cells.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.